Blog
RSS FeedPosted by Michael Wonder on 11 Oct 2024
Roche Canada announces Columvi (glofitamab for injection) is publicly reimbursed in 7 provinces, including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia and Newfoundland
9 October 2024 - Columvi is now publicly covered in 7 provinces, which equates to approximately 74% of the total Canadian ...
Posted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...
Posted by Michael Wonder on 30 Sep 2023
Medison Pharma announces public formulary listing of Qinlock (ripretinib) in Canadian provinces: Ontario and Quebec for advanced gastro-intestinal stromal tumour treatment
29 September 2023 - Medison Pharma is pleased to announce the public formulary listing of Qinlock in Canadian provinces: Ontario ...
Posted by Michael Wonder on 19 Aug 2023
Quebec becomes the first province to reimburse Minjuvi (tafasitamab) in combination with lenalidomide for patients with diffuse large B-cell lymphoma
17 August 2023 - This is the first public listing since Minjuvi was approved with conditions by Health Canada in ...
Posted by Michael Wonder on 10 Aug 2023
Patient and citizen participation at the organisational level in health technology assessment: an exploratory study in five jurisdictions
8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...
Posted by Michael Wonder on 13 Jul 2023
Slynd (drospirenone) is now covered by the Régie de l’assurance maladie du Québec
12 July 2023 - Duchesnay is pleased to announce that Slynd (drospirenone 4 mg), used to prevent pregnancy in girls ...
Posted by Michael Wonder on 18 Apr 2023
AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec
17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...
Posted by Michael Wonder on 09 Feb 2023
Quebec becomes first province to cover Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinemia
6 February 2023 - First and only Bruton's tyrosine kinase inhibitor to be granted provincial formulary approval. ...
Posted by Michael Wonder on 07 Feb 2023
Valeo Pharma obtains public reimbursement for Onstryv in Quebec
7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec. ...
Posted by Michael Wonder on 02 Feb 2023
Medexus secures public reimbursement for Cuvposa in Quebec
1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...
Posted by Michael Wonder on 03 Dec 2022
AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...
Posted by Michael Wonder on 17 Oct 2022
Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss
17 October 2022 - Quebec leads the way as the first province to reimburse Luxturna (voretigene neparvovec) for previously untreatable inherited ...
Posted by Michael Wonder on 24 May 2022
HLS Therapeutics obtains public reimbursement for Vascepa in Quebec
24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...
Posted by Michael Wonder on 03 May 2022
Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases
3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...